M. Nieto, J. Borregaard, J. Ersboll, G. Bosch, B. Van-zwieten-boot et al., The European Medicines Agency Review of Pazopanib for the Treatment of Advanced Renal Cell Carcinoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use, Clinical Cancer Research, vol.17, issue.21, pp.6608-6614, 2011.
DOI : 10.1158/1078-0432.CCR-11-1734

N. Nagai, M. Kinoshita, H. Ogata, D. Tsujino, Y. Wada et al., Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients, Cancer Chemotherapy and Pharmacology, vol.39, issue.1-2, pp.131-137, 1996.
DOI : 10.1007/s002800050548

A. Leroy, M. Wehling, H. Sponseller, W. Friauf, R. Solomon et al., Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry, Biochemical Medicine, vol.18, issue.2, pp.184-191, 1977.
DOI : 10.1016/0006-2944(77)90089-8

S. Urien and F. Lokiec, Population pharmacokinetics of total and unbound plasma cisplatin in adult patients, British Journal of Clinical Pharmacology, vol.38, issue.6, pp.756-763, 2004.
DOI : 10.1046/j.1365-2125.1996.04231.x

D. Imbs, S. Negrier, P. Cassier, A. Hollebecque, A. Varga et al., Pharmacokinetics of pazopanib administered in combination with bevacizumab, Cancer Chemotherapy and Pharmacology, vol.37, issue.Suppl 1, pp.1189-1196, 2014.
DOI : 10.1016/j.ctrv.2010.08.006

H. Hurwitz, A. Dowlati, S. Saini, S. Savage, A. Suttle et al., Phase I Trial of Pazopanib in Patients with Advanced Cancer, Clinical Cancer Research, vol.15, issue.12, pp.4220-4227, 2009.
DOI : 10.1158/1078-0432.CCR-08-2740

E. Cvitkovic, D. Hayes, R. Golbey, and I. Krakoff, Cisplatin nephrotoxicity: diethyldithiocarbamate, WR2721, or just water?, Journal of Clinical Oncology, vol.9, issue.4, pp.707-709, 1991.
DOI : 10.1200/JCO.1991.9.4.707

S. Ekins, S. Andreyev, A. Ryabov, E. Kirillov, E. Rakhmatulin et al., A COMBINED APPROACH TO DRUG METABOLISM AND TOXICITY ASSESSMENT, Drug Metabolism and Disposition, vol.34, pp.495-503, 2006.
DOI : 10.1124/dmd.105.008458

URL : http://dmd.aspetjournals.org/content/dmd/34/3/495.full.pdf

S. Keisner and S. Shah, Pazopanib, Drugs, vol.71, pp.443-454, 2011.
DOI : 10.2165/11588960-000000000-00000

M. Aapro and C. Walko, Aprepitant: drug-drug interactions in perspective, Annals of Oncology, vol.11, issue.3, pp.2316-2323, 2010.
DOI : 10.1200/JCO.2006.06.9591

URL : https://academic.oup.com/annonc/article-pdf/21/12/2316/499758/mdq149.pdf

W. Loos, R. De-wit, S. Freedman, K. Van-dyck, J. Gambale et al., Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients, Cancer Chemotherapy and Pharmacology, vol.56, issue.3, pp.407-412, 2007.
DOI : 10.1016/j.ejca.2003.08.028

P. Nygren, K. Hande, K. Petty, M. Fedgchin, K. Van-dyck et al., Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients, Cancer Chemotherapy and Pharmacology, vol.36, issue.6, pp.609-616, 2005.
DOI : 10.1007/s00280-004-0946-3

B. Vincenzi, G. Tonini, and D. Santini, Aprepitant for Erlotinib-Induced Pruritus, New England Journal of Medicine, vol.363, issue.4, pp.397-398, 2010.
DOI : 10.1056/NEJMc1003937

C. Shadle, Y. Lee, A. Majumdar, K. Petty, C. Gargano et al., Evaluation of Potential Inductive Effects of Aprepitant on Cytochrome P450 3A4 and 2C9 Activity, The Journal of Clinical Pharmacology, vol.254, issue.3, pp.215-223, 2004.
DOI : 10.1006/bbrc.1998.9992

H. Burris, . Iii, A. Dowlati, R. Moss, J. Infante et al., Phase I Study of Pazopanib in Combination with Paclitaxel and Carboplatin Given Every 21 Days in Patients with Advanced Solid Tumors, Molecular Cancer Therapeutics, vol.11, issue.8, pp.1820-1828, 2012.
DOI : 10.1158/1535-7163.MCT-11-0997

A. Bonetti, T. Franceschi, P. Apostoli, A. Messori, L. Sperotto et al., Cisplatin Pharmacokinetics Using a Five-Day Schedule During Repeated Courses of Chemotherapy in Germ Cell Tumors, Therapeutic Drug Monitoring, vol.17, issue.1, pp.25-32, 1995.
DOI : 10.1097/00007691-199502000-00005

P. Daley-yates and D. Mcbrien, Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin, Biochemical Pharmacology, vol.33, issue.19, pp.3063-3070, 1984.
DOI : 10.1016/0006-2952(84)90610-5

A. Majumdar, J. Mccrea, D. Panebianco, M. Hesney, J. Dru et al., Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe, Clinical Pharmacology & Therapeutics, vol.74, issue.2, pp.150-156, 2003.
DOI : 10.1016/S0009-9236(03)00123-1

B. Goh, N. Reddy, U. Dandamudi, K. Laubscher, T. Peckham et al., An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors, Clinical Pharmacology & Therapeutics, vol.48, issue.5, pp.652-659, 2010.
DOI : 10.1038/clpt.2010.158

A. Suttle, H. Ball, M. Molimard, T. Hutson, C. Carpenter et al., Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma, British Journal of Cancer, vol.8, issue.10, pp.1909-1916, 2014.
DOI : 10.1097/FTD.0b013e3181b2c8cf

URL : http://www.nature.com/bjc/journal/v111/n10/pdf/bjc2014503a.pdf